Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801824 | 1.00 | LMNA (0.42) | LMNAALDH1A1TSHRTDP1LGALS1 | |
| SCHEMBL15142 | 0.96 | — | — | |
| SCHEMBL18457024 | 0.94 | LMNA (0.39) | LMNAALDH1A1TSHRTDP1LGALS1 | |
| SCHEMBL20115301 | 0.94 | LMNA (0.39) | LMNAALDH1A1TSHRTDP1LGALS1 | |
| SCHEMBL19055971 | 0.94 | LMNA (0.39) | LMNAALDH1A1TSHRTDP1LGALS1 | |
| SCHEMBL24103701 | 0.94 | LMNA (0.39) | LMNAALDH1A1TSHRTDP1LGALS1 | |
| SCHEMBL19055972 | 0.94 | LMNA (0.39) | LMNAALDH1A1TSHRTDP1LGALS1 | |
| SCHEMBL18904585 | 0.84 | ALDH1A1 (0.33) | LMNAALDH1A1TSHRTDP1LGALS1 | |
| SCHEMBL28456182 | 0.83 | — | — | |
| SCHEMBL19255677 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102770469-B | Method for producing water-absorbing polymer particles having improved color stability | BASF SE | 2015-04-15 | — | — | CN | claimed |
| US-8497337-B2 | Process for producing water-absorbing polymer particles with improved color stability | BASF SE (DE) | 2013-07-30 | — | — | US | claimed |
| US-20110121230-A1 | Process for Producing Water-Absorbing Polymer Particles with Improved Color Stability | BASF SE (DE) | 2011-05-26 | — | — | US | claimed |
| EP-4263558-B1 | MACROCYCLIC BRANCHED 3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-12 | — | — | EP | disclosed |
| US-12092644-B2 | Kits comprising aldehydes to reduce artifacts in analyzing glycans released from glycoproteins or glycopeptides | AGILENT TECHNOLOGIES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-3500842-B1 | USE OF MILD ELECTROPHILES TO REDUCE ARTIFACTS IN ANALYZING GLYCANS RELEASED FROM GLYCOPROTEINS OR GLYCOPEPTIDES | AGILENT TECHNOLOGIES INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240083890-A1 | MACROCYCLIC BRANCHED 3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-14 | — | — | US | disclosed |
| EP-4263558-A1 | MACROCYCLIC BRANCHED 3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | JANSSEN Pharmaceutica NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022129331-A1 | MACROCYCLIC BRANCHED 3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-23 | — | — | WO | disclosed |
| US-11035862-B2 | Use of mild electrophiles to reduce artifacts in analyzing glycans released from glycoproteins or glycopeptides | AGILENT TECHNOLOGIES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11035862-B2 | Use of mild electrophiles to reduce artifacts in analyzing glycans released from glycoproteins or glycopeptides | AGILENT TECHNOLOGIES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2010132839-A2 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132760-A1 | ANTIBACTERIAL DERIVATIVES OF TOBRAMYCIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132759-A1 | ANTIBACTERIAL DERIVATIVES OF DIBEKACIN | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | GORDIAN PHARMA LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| WO-2010042850-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| US-20080308426-A1 | Electrochemical Method for the Production of Betulin Aldehyde | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2008-12-18 | — | — | US | disclosed |
| WO-2008046232-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | YUDIN ANDREI K (CA) | 2008-04-24 | — | — | WO | disclosed |
| WO-2007074344-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | MORVUS TECHNOLOGY LIMITED (GB) | 2007-07-05 | — | — | WO | disclosed |
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104515-A1 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS | DERA, HOGA1, ALDOA | LMNA 763/4885ALDH1A1 78/4885TSHR 4884/4885 |
| US-20240083890-A1 | MACROCYCLIC BRANCHED 3-FLUORO-BUT-3-ENAMIDES AS INHIBITORS OF MCL-1 | MCL1, BCL3, BCL2L1 | LMNA 743/4885ALDH1A1 409/4885TSHR 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.